PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10705995-11 1999 After 24 h of exposure of T47-D cells to either 1 or 10 microM progesterone, we observed a marked down-regulation of protooncogene bcl-2 protein and mRNA levels. Progesterone 63-75 BCL2 apoptosis regulator Homo sapiens 131-136 11776191-10 2000 Analysis on expression of intracellular bcl-2 protein showed that progesterone could down-regulate bcl-2 protein and at concentration of 1 x 10(-5) mol/L it could almost block bcl-2 expression. Progesterone 66-78 BCL2 apoptosis regulator Homo sapiens 40-45 11776191-10 2000 Analysis on expression of intracellular bcl-2 protein showed that progesterone could down-regulate bcl-2 protein and at concentration of 1 x 10(-5) mol/L it could almost block bcl-2 expression. Progesterone 66-78 BCL2 apoptosis regulator Homo sapiens 99-104 11776191-10 2000 Analysis on expression of intracellular bcl-2 protein showed that progesterone could down-regulate bcl-2 protein and at concentration of 1 x 10(-5) mol/L it could almost block bcl-2 expression. Progesterone 66-78 BCL2 apoptosis regulator Homo sapiens 99-104 11751611-9 2002 Progesterone and 19-norprogesterone, alone or in combination with estrogen, increased Bcl-2 expression. Progesterone 0-12 BCL2 apoptosis regulator Homo sapiens 86-91 34106437-8 2021 Progesterone stimulation alone as well as co-stimulation with TNF-alpha, NGAL, IL-18, IL-1beta, or thrombin with progesterone either increased, decreased, or did not change the expression of Bcl-2, Bcl-XL, or XIAP genes (anti-apoptotic factors). Progesterone 0-12 BCL2 apoptosis regulator Homo sapiens 191-196 9846203-0 1998 Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53. Progesterone 0-12 BCL2 apoptosis regulator Homo sapiens 94-99 9306964-0 1997 Down-regulation of bcl-2 expression is closely related to squamous differentiation and progesterone therapy in endometrial carcinomas. Progesterone 87-99 BCL2 apoptosis regulator Homo sapiens 19-24 9306964-7 1997 In addition, bcl-2 expression appears to be down-regulated by progesterone therapy through tumour cell maturation, indicating that bcl-2 may be a clinically useful marker of hormone therapy effects. Progesterone 62-74 BCL2 apoptosis regulator Homo sapiens 13-18 9306964-7 1997 In addition, bcl-2 expression appears to be down-regulated by progesterone therapy through tumour cell maturation, indicating that bcl-2 may be a clinically useful marker of hormone therapy effects. Progesterone 62-74 BCL2 apoptosis regulator Homo sapiens 131-136 8989276-0 1997 Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. Progesterone 90-102 BCL2 apoptosis regulator Homo sapiens 24-29 8989276-8 1997 In monolayer cultures of uterine leiomyoma cells under a serum-free condition, the addition of progesterone (100 ng/mL) resulted in a striking increase in Bcl-2 protein expression in the cultured leiomyoma cells relative to that in control cultures, whereas the addition of 17 beta-estradiol (10 ng/mL) resulted in a reduction in Bcl-2 protein expression in the cells. Progesterone 95-107 BCL2 apoptosis regulator Homo sapiens 155-160 8989276-8 1997 In monolayer cultures of uterine leiomyoma cells under a serum-free condition, the addition of progesterone (100 ng/mL) resulted in a striking increase in Bcl-2 protein expression in the cultured leiomyoma cells relative to that in control cultures, whereas the addition of 17 beta-estradiol (10 ng/mL) resulted in a reduction in Bcl-2 protein expression in the cells. Progesterone 95-107 BCL2 apoptosis regulator Homo sapiens 330-335 10434946-8 1999 These data indicate that antiprogestin administration inhibits progesterone downregulation of steroid receptors in endometrial glands, resulting in persistence of a proliferative endometrium and accompanying bcl-2 secretion. Progesterone 63-75 BCL2 apoptosis regulator Homo sapiens 208-213 9390034-0 1997 Variation of bcl-2 expression in breast ducts and lobules in relation to plasma progesterone levels: overexpression and absence of variation in fibroadenomas. Progesterone 80-92 BCL2 apoptosis regulator Homo sapiens 13-18 9390034-9 1997 This was further supported by a statistical link (P = 5 x 10(-3) between high levels of circulating progesterone and weak bcl-2 staining in lobules and ducts. Progesterone 100-112 BCL2 apoptosis regulator Homo sapiens 122-127 34106437-8 2021 Progesterone stimulation alone as well as co-stimulation with TNF-alpha, NGAL, IL-18, IL-1beta, or thrombin with progesterone either increased, decreased, or did not change the expression of Bcl-2, Bcl-XL, or XIAP genes (anti-apoptotic factors). Progesterone 113-125 BCL2 apoptosis regulator Homo sapiens 191-196 18444248-13 2008 The addition of progesterone (100 ng/mL) resulted in a striking increase in Bcl-2 protein expression in the cultured leiomyoma cells. Progesterone 16-28 BCL2 apoptosis regulator Homo sapiens 76-81 33074834-7 2020 Results: Compared to the control group, we observed a significant increase in the expression levels of the Bax and P53 genes and the activity levels of caspase-3 and 9, and a significant decrease in the expression level of the Bcl-2 gene in MCF-7 and MG-63 treated with effective concentration of progesterone. Progesterone 297-309 BCL2 apoptosis regulator Homo sapiens 227-232 31696694-9 2019 Moreover, progesterone could induce progesterone receptor M to up-regulate apoptotic protein Caspase-3 and down-regulate anti-apoptotic protein Bcl-2, thus it could inhibit the apoptosis of primary cultured uterine leiomyoma cells and promote the proliferation of leiomyoma cells. Progesterone 10-22 BCL2 apoptosis regulator Homo sapiens 144-149 27538988-12 2016 Nuclear protein analysis by electrophoretic mobility shift assay showed the association of progesterone with progesterone response element (PRE), which may lead to downregulation of Bcl-2. Progesterone 91-103 BCL2 apoptosis regulator Homo sapiens 182-187 27538988-12 2016 Nuclear protein analysis by electrophoretic mobility shift assay showed the association of progesterone with progesterone response element (PRE), which may lead to downregulation of Bcl-2. Progesterone 109-121 BCL2 apoptosis regulator Homo sapiens 182-187 32244545-7 2020 The anticancer effects were mediated by increased caspase-3, BAX, and decreased BCL2 and PARP-1 expression in DDP and progesterone-calcitriol combination-treated cells. Progesterone 118-130 BCL2 apoptosis regulator Homo sapiens 80-84 31669405-9 2020 After steroid treatment of damaged retinas, BCL-XL, BCL2 and BAX showed characteristic patterns depending on the use of dexamethasone or progesterone on mifepristone or light exposed retinas. Progesterone 137-149 BCL2 apoptosis regulator Homo sapiens 52-56 31288815-12 2019 Our studies demonstrated that five PRGs including Bcl2, FOXO1A, SCGB2A2, CYP26a1 and MMP11 exhibited significant progesterone-hyper-responsiveness in human PrMyoF cells as compared to PrMyoN cells (P < 0.05). Progesterone 113-125 BCL2 apoptosis regulator Homo sapiens 50-54 25113166-3 2014 By examining the interactions of estradiol (E2) and progesterone (P4) in women, we propose that changes in physiologic reproductive hormone templates of exposure and timing can affect fertility and even cancer through the silencing or amplification of gene products; such as P53 and Bcl-2 in women. Progesterone 52-64 BCL2 apoptosis regulator Homo sapiens 283-288 16138714-7 2005 As predicted, progesterone successfully downregulated anti-apoptotic Bcl-2 expression, and dose-dependently suppressed Bcl-2 expression in tumor cells. Progesterone 14-26 BCL2 apoptosis regulator Homo sapiens 69-74 19205434-3 2008 Several factors have been speculated to affect the induction of Bcl-2 in these cells, including progesterone, endoplasmic reticulum stress, and microRNAs. Progesterone 96-108 BCL2 apoptosis regulator Homo sapiens 64-69 17785366-5 2007 It was proposed that growth enhancement of leiomyoma cells by progesterone was mediated via bcl-2 induction. Progesterone 62-74 BCL2 apoptosis regulator Homo sapiens 92-97 17785366-9 2007 Transient transfection with deletion mutants of bcl-2 promoter showed that the -1281/-258-bp region conferred responsiveness to progesterone induction in the presence of PR-A. Progesterone 128-140 BCL2 apoptosis regulator Homo sapiens 48-53 16138714-7 2005 As predicted, progesterone successfully downregulated anti-apoptotic Bcl-2 expression, and dose-dependently suppressed Bcl-2 expression in tumor cells. Progesterone 14-26 BCL2 apoptosis regulator Homo sapiens 119-124 15779298-0 2005 [Protein bcl-2 expression in the secretory endometrium after oral estrogen-progesterone replacement]. Progesterone 75-87 BCL2 apoptosis regulator Homo sapiens 9-14 15140868-5 2004 17beta-Estradiol up-regulates epidermal growth factor (EGF) receptor, but down-regulates p53 protein in leiomyoma cells, whereas progesterone augments EGF and Bcl-2 protein, but inhibits insulin-like growth factor (IGF-I) and tumour necrosis factor (TNFalpha). Progesterone 129-141 BCL2 apoptosis regulator Homo sapiens 159-164